{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:48:48Z","timestamp":1789156128033,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":653,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2000,3,11]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. The effects of dopaminergic agonists and antagonists were investigated on withdrawal signs in lorazepam\u2010dependent rats. Physical dependence was developed by giving lorazepam admixed with food in the following dose schedules: 10 \u00d7 4, 20 \u00d7 4, 40 \u00d7 4, 80 \u00d7 4 and 120 \u00d7 7 mg\/kg, daily for x days.<\/jats:p><jats:p>2. The parameters observed during the periods of administration of lorazepam and after its withdrawal were spontaneous locomotor activity (SLA), reaction time to pain, foot shock aggression (FSA) and audiogenic seizures.<\/jats:p><jats:p>3. During the withdrawal period, rats were divided into groups of 10 rats each. One group did not receive any drug and served as the control withdrawal groups. Three other groups received, separately, one of the following dopamimetic drugs: (i) 200 mg\/kg per day, i.m., <jats:sc>L<\/jats:sc>\u2010dihydroxyphenylalanine (DOPA; +50 mg\/kg per day, i.m., carbidopa); (ii) 2 mg\/kg per day, i.m., amphetamine; or (iii) 1 mg\/kg per day, i.m., apomorphine. The remaining groups received one of the following dopamine antagonists: (i) 0.1 mg\/kg per day, i.m., SCH 23390; (ii) 0.5 mg\/kg per day, i.m., haloperidol; (iii) 0.5 mg\/kg per day, i.m., centbutindol; and (iv) either 1 or 20 mg\/kg per day, i.m., clozapine.<\/jats:p><jats:p>4. The withdrawal signs observed in the control group were hyperkinesia, hyperaggression and audiogenic seizures.<\/jats:p><jats:p>5. <jats:sc>L<\/jats:sc>\u2010Dihydroxyphenylalanine (+ carbidopa), amphetamine and apomorphine potentiated hyperaggression and audiogenic seizures. The dopamine D2 receptor antagonists haloperidol, centbutindol and clozapine (at 20 mg\/kg, i.m.) blocked all withdrawal signs. The D1 receptor antagonist SCH 23390 inhibited hyperkinesia and hyperaggression. The D4 receptor antagonist clozapine (at 1 mg\/kg, i.m.) had no effect on any of the withdrawal signs.<\/jats:p><jats:p>6. It may be concluded that dopamine D2 receptors exert a dominant facilitatory influence, with partial contribution of D1 receptors, on the benzodiazepine withdrawal syndrome.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2000.03219.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:05:57Z","timestamp":1047380757000},"page":"167-171","source":"Crossref","is-referenced-by-count":12,"title":["Effect Of Dopamine Agonists And Antagonists On The Lorazepam Withdrawal Syndrome In Rats"],"prefix":"10.1111","volume":"27","author":[{"given":"C","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rc","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mb","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.280.6224.1163-a"},{"key":"e_1_2_6_3_2","unstructured":"TyrerPJ&SeivewrightN.Identification and management of benzodiazepine dependence.\u25caPostgrad. Med. J.1984;60(Suppl. 2): 41\u20136."},{"key":"e_1_2_6_4_2","unstructured":"HobbsWR RallTW VerdoornTA.Sedatives and hypnotics: Ethanol. In: Hardman JG Limbird LE Molinoff PB Rudden RW Gillman AG (eds).Goodman and Gillman\u2019s the Pharmacological Basis of Therapeutics 9th edn. MacGraw\u2013Hill New York. 1996: 361\u201398."},{"key":"e_1_2_6_5_2","unstructured":"WoodJH KatzJL WingerG.Abuse and therapeutic use of benzodiazepine and benzodiazepine\u2010like drugs. In: Bloom BE Kupfer DJ (eds).Psychopharmacology. The Fourth Generation of Progress.Raven Press New York. 1995; 1777\u201392."},{"key":"e_1_2_6_6_2","first-page":"13","article-title":"Comparative evaluation of physical dependence of some benzodiazepines in rats.","volume":"4","author":"Gupta MB","year":"1993","journal-title":"Ann. Neurosci."},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","unstructured":"GuptaGP GuptaMB NathC SrimalRC DhawanBN.Effect of some CNS active drugs on methaqualone abstinence.Eur. J. Pharmacol.1990;183: 577.","DOI":"10.1016\/0014-2999(90)93466-4"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.25.453"},{"key":"e_1_2_6_9_2","first-page":"310","article-title":"Effect of calcium channel blockers on withdrawal syndrome of lorazepam in rats.","volume":"103","author":"Gupta MB","year":"1996","journal-title":"Ind. J. Med. Res."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1953.tb00749.x"},{"key":"e_1_2_6_11_2","first-page":"73","article-title":"The antiparkinsonian effects of some drugs as determined by Haffner\u2019s method of testing analgesia in mice.","volume":"124","author":"Chen G.","year":"1958","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_12_2","first-page":"28","article-title":"Effects of various centrally acting drugs on fighting behaviour of mice.","volume":"125","author":"Tedeschi RE","year":"1959","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(66)90055-4"},{"key":"e_1_2_6_14_2","unstructured":"O\u2019BrienCP.Drug addiction and drug abuse. In: Hardman JG Limbird LE Molinoff PB Rudden RW Gillman AG (eds).Goodman and Gillman\u2019s the Pharmacological Basis of Therapeutics 9th edn. MacGraw\u2013Hill New York. 1996; 581\u2013600."},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","unstructured":"DhawanKN NathC KumarA GuptaGP.A study of some neurotransmitters in foot shock induced aggression.Eur. J. Pharmacol.1990;183: 1385.","DOI":"10.1016\/0014-2999(90)94512-V"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb03224.x"},{"key":"e_1_2_6_17_2","unstructured":"SeemanP.Dopaminergic receptors: Clinical correlates. In: Bloom FE Kupfer DJ (eds).Psychopharmacology. The Fourth Generation of Progress. Raven Press New York. 1995; 295\u2013302."},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","unstructured":"PalitG DonkerMG NathCet al.Evidence for dopamine receptor blocking activity of centbutindol a new neuroleptic.Eur. J Pharmacol. 1990;183: 1886.","DOI":"10.1016\/0014-2999(90)92224-7"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2000.03219.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2000.03219.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T12:25:51Z","timestamp":1698582351000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2000.03219.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,11]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3,11]]}},"alternative-id":["10.1046\/j.1440-1681.2000.03219.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2000.03219.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,11]]}}}